Current Report Filing (8-k)
August 10 2020 - 6:57AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): August 10, 2020
Protalix
BioTherapeutics, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-33357
|
|
65-0643773
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
2 Snunit Street
|
|
|
Science Park, POB 455
|
|
|
Carmiel, Israel
|
|
2161401
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
|
|
|
|
|
|
Registrant’s telephone number, including area
code +972-4-988-9488
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communication pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, $0.001 par value
|
PLX
|
NYSE American
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 2.02
|
Results of Operations and Financial Condition
|
On August 10, 2020, Protalix BioTherapeutics, Inc. (the
“Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2020,
and provided a business update on recent corporate and clinical developments. A copy of the press release is furnished as Exhibit
99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under
the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such
filing.
|
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 10, 2020
|
PROTALIX BIOTHERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Dror Bashan
|
|
|
|
Name:
|
Dror Bashan
|
|
|
|
Title:
|
President and Chief Executive Officer
|
|
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Sep 2023 to Sep 2024